Aeolus Pharmaceuticl (AOLS) 0.3000 $AOLS Aeolus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeolus Pharmaceuticl (AOLS) 0.3000 $AOLS

Aeolus Pharmaceuticals reports Barda's exercises of USD3m in additional contract funding for development of AEOL 10150 for Acute Radiation Syndrome
M2 - Mon Jun 29, 3:19AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) disclosed on Friday the exercise of USD3m in additional contract options for AEOL 10150 by Biomedical Advanced Research and Development Authority (BARDA) under the USD118m advanced research and development contract.

Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome
Marketwired - Fri Jun 26, 7:00AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that the Biomedical Advanced Research and Development Authority (BARDA) exercised $3 million in additional contract options under its advanced research and development contract for AEOL 10150. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats.

Gastrointestinal Radiation Toxicity Pipeline Review, H1 2015 - 3 Companies & 5 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xrv6c/gastrointestinal) has announced the addition of the "Gastrointestinal Radiation Toxicity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Radiation Toxicity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Radiation Toxicity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeolus Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - Soligenix, Inc. Drug Profiles - 2A2 - AEOL-10150 - AVX-470 - m2A2 - SGX-202 For more information visit http://www.researchandmarkets.com/research/9x...intestinal

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 388.23 (-11.06), ASPX: 100.96 (unch), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), GILD: 113.74 (+0.38), CGEN: 6.63 (+0.06), IBIO: 0.86 (+0.01), FGEN: 22.82 (+0.58), CELGZ: 2.15 (+0.14), FPRX: 26.01 (+0.37)

Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
Marketwired - Thu May 28, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the LD Micro Invitational Conference on Tuesday, June 2nd, 2015 at 11:30 AM PDT (2:30 PM EDT) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. Cavalier will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA" . The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS" following a nuclear event.

Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review 2015
M2 - Wed May 27, 11:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rz8t2h/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aeolus Pharmaceuticals, Inc. - Bolder Biotechnology, Inc. - Cantex Pharmaceuticals, Inc. - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Gamida Cell Ltd. - Humanetics Corporation - Meabco A/S - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Piramal Enterprises Limited - Pluristem Therapeutics Inc. - Priaxon AG - ProCertus BioPharm Inc. - RDD Pharma Ltd. - RxBio, Inc. - Soligenix, Inc. - Terapio Corporation - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/rz8t2h/radiation
TNXP: 8.22 (-0.36), PSTI: 2.40 (+0.03), NBS: 2.25 (-0.09), ONTX: 2.51 (-0.09), CBLI: 3.78 (+0.17)

Aeolus Announces Second Quarter Fiscal Year 2015 Financial Results
Marketwired - Fri May 15, 3:53PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and six months ended March 31, 2015.

Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwired - Mon May 04, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)

Aeolus Pharmaceuticals, Inc. - Product Pipeline Review - 2015
M2 - Fri Apr 17, 2:46AM CDT
This report provides comprehensive information on the current therapeutic developmental pipeline of Aeolus Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Aeolus Files Patent Application and Completes Licensure of New Series of Compounds to Treat Infectious and Inflammatory Disease
Marketwired - Wed Apr 15, 7:01AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has filed a provisional patent application with the United States Patent Office for a new series of compounds demonstrating anti-microbial and anti-inflammatory action. The compounds were developed by Brian J. Day, PhD at National Jewish Health in Denver, Colorado as a result of an Aeolus-sponsored research grant. Aeolus also announced that it has obtained a worldwide, exclusive license to develop the compounds from National Jewish Health.

Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas
Marketwired - Tue Mar 31, 7:03AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received a Notice of Allowance from the Israeli Patent Office for application number 209435, "Methods for Treating Injury Associated with Exposure to an Alkylating Species." The patent covers Aeolus' lead compound, AEOL 10150 as well as other metalloporphyrins under development by the Company. Alkylating agents include chemical gas agents such as sulfur mustard gas.

Aeolus wins US FDA's orphan drug designation for AEOL 10150 for treating idiopathic pulmonary fibrosis
M2 - Wed Mar 18, 6:55AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).

Aeolus Pharma antioxidant an Orphan Drug for lung disease
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 12:38PM CDT


Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Marketwired - Tue Mar 17, 10:46AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for treatment of idiopathic pulmonary fibrosis." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 81

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 178

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 88

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 95

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 189

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading

Top 5 Most Recently Viewed Articles

Stocks Poised for Growth in Light of China's Rate Cuts

Updated Category News Views 81

Stocks Poised for Growth in Light of China's Rate Cuts As interest rates in China witness a significant reduction, investors' attention has naturally gravitated towards key Chinese stocks, which are experiencing renewed interest and rapid rallies. However, it may be wise to look beyond these familiar names and consider other companies that stand to benefit indirectly from...

Continue Reading
Vapotherm and Flight Medical Forge New Path for Ventilators

Updated Category News Views 264

Vapotherm and Flight Medical Forge New Path for Ventilators In a significant move for critical care, Vapotherm, Inc. has partnered with Flight Medical Innovations Ltd. to introduce the VentO2ux™ ventilator to hospitals throughout the United States. This collaboration marks a pivotal expansion for Vapotherm, known for its advanced respiratory support technologies, by...

Continue Reading
C1Risk Chosen to Enhance Government GRC Capabilities

Updated Category News Views 222

C1Risk Selected for Statewide Public Benefits System A major government organization has opted for C1Risk as its platform for Governance, Risk, and Compliance (GRC). This decision represents a crucial advancement in modernizing oversight within public benefits systems, highlighting the increasing necessity for efficient compliance automation for government entities....

Continue Reading
Exploring the Growth of the Self-Adhesive Tear Tapes Market

Updated Category News Views 151

Growth Potential of the Self-Adhesive Tear Tapes Market The self-adhesive tear tapes market is poised for substantial growth, projected to reach $281.9 million as demand for secure and convenient packaging continues to rise. This growth trajectory emphasizes not only the popularity of these tapes across various industries but also reflects ongoing advancements in...

Continue Reading
Shandong Radio and Television Station's Documentary Event Enriches Cultural Exchange

Updated Category News Views 154

Shandong Radio and Television Station's Documentary Event at a Prestigious University In an exciting collaboration, Shandong Radio and Television Station, along with its partner organizations, recently hosted a documentary promotion and screening event at a prominent university. This event provided an incredible opportunity for students and faculty to immerse themselves...

Continue Reading